1-(2-羟基苯基)哌嗪盐酸盐

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(2-羟基苯基)哌嗪盐酸盐
• 英文名称: 1-(2-hydroxyphenyl)piperazine hydrochloride
• 英文别名: 4-(2-hydroxyphenyl)piperazin-1-ium chloride；2-hydroxyphenyl-piperazine monohydrochloride；2-Piperazin-4-ium-1-ylphenol;chloride；2-piperazin-4-ium-1-ylphenol;chloride
• 化学式: C₁₀H₁₄N₂O*ClH
• mdl: MFCD22378691
• 分子量: 214.695
• InChiKey: UQMMJMAMYMNLTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.0
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  35.5
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-羟基苯基)哌嗪盐酸盐 在 盐酸 、 盐酸羟胺 作用下， 以 乙醇 为溶剂， 反应 25.0h， 生成 1-(3-methylbenzo[b]thiophen-2-yl)-3-[4-(2-hydroxyphenyl)piperazin-1-yl]propan-1-one oxime
  参考文献：
  名称：

  Orus; Sainz; Perez, Pharmazie, 2002, vol. 57, # 6, p. 355 - 357

  摘要：

  DOI：
• 作为产物：
  描述：

  二(2-氯乙基)胺盐酸盐 、 2-氨基苯酚 以 环丁砜 为溶剂， 反应 14.0h， 以87%的产率得到1-(2-羟基苯基)哌嗪盐酸盐
  参考文献：
  名称：

  An efficient scale up process for synthesis of N-arylpiperazines

  摘要：

  An efficient protocol for the synthesis of various substituted phenylpiperazines was developed using sulfolane as solvent. The protocol was clean, high yielding and products were obtained in high purities (>= 99%). It was also fast and convenient, as the final products were precipitated as hydrochloride salts and could be obtained by filtration. Sulfolane, an aprotic, dipolar, high boiling and recoverable solvent was used as a substitute for common organic solvents. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2015.06.003

文献信息

• [EN] METABOLITES OF 1-{3-4`4-(2-METHOXYPHENYL) PIPERAZIN-1-YL!-PROPYL}-PIPERIDINE-2, 6-DIONE FOR USE IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA<br/>[FR] METABOLITES DE 1-{3-4`4-(2-METHOXYPHENYL)PIPERAZIN-1-YL!-PROPYL}-PIPERIDINE-2, 6-DIONE UTILISABLES DANS LE TRAITEMENT DE L'HYPERTROPHIE BENIGNE DE LA PROSTATE
  申请人：RANBAXY LAB LTD

  公开号：WO2005018643A1

  公开（公告）日：2005-03-03

  The present invention relates to the metabolites of 1-3-[4-(2-Methoxyphenyl) piperazin-1-yl]-propyl}-piperidine-2, 6-dione of Formula (I). The disclosed compounds can function as α1a-adrenceptor antagonists and thus can be used for the treatment of benign prostatic hyperplasia (BPH) and related symptoms thereof. Processes for the preparation of the metabolites, pharmaceutical compositions containing these metabolites and the method of treating BPH and related symptoms thereof are also disclosed.

  本发明涉及公式（I）的1-3-[4-(2-甲氧基苯基)哌嗪-1-基]-丙基}-哌啶-2,6-二酮的代谢产物。所公开的化合物可以作为α1a-肾上腺素受体拮抗剂，因此可用于治疗良性前列腺增生（BPH）及其相关症状。还公开了制备这些代谢产物的方法、含有这些代谢产物的药物组合物以及治疗BPH及其相关症状的方法。
• HYDROQUINONE DERIVATIVES
  申请人：——

  公开号：US20010008893A1

  公开（公告）日：2001-07-19

  A hydroquinone derivative useful as an intraocular pressure lowering, anti-hypertensive and radical scavenging agent represented by the following formula 1 wherein B 1 and B 2 in formula (I) are the same or different and at any position on the benzene ring (when W is nitrogen, however, at any other position on the benzene ring) and each denotes a substituent selected from the group consisting of hydrogen, halogen, hydroxyl, lower alkoxyl and carboxyl, and the substituent CH 3 is at position 2 or 3, and W are the same or different and each denotes a nitrogen or carbon atom. R 1 , R 2 , R 3 and R 4 in formula (II) are the same or different and each denotes a substituent selected from the group consisting of hydrogen, lower alkyl and lower alkoxyl, and B 1 and B 2 are as hereinbefore defined, or a pharmacologically acceptable salt thereof.

  一种具有降低眼内压、抗高血压和自由基清除作用的有用氢醌衍生物，由以下式1表示，其中式（I）中的B1和B2相同或不同，并且在苯环上的任何位置（当W为氮时，在苯环上的任何其他位置），每个表示从氢、卤素、羟基、低级烷氧基和羧基组成的组中选择的取代基，并且取代基CH3位于位置2或3，并且W相同或不同，每个表示氮或碳原子。式（II）中的R1、R2、R3和R4相同或不同，每个表示从氢、低级烷基和低级烷氧基组成的组中选择的取代基，并且B1和B2如前所述，或其药理学上可接受的盐。
• New 1-Aryl-3-(4-arylpiperazin-1-yl)propane Derivatives, with Dual Action at 5-HT_1A Serotonin Receptors and Serotonin Transporter, as a New Class of Antidepressants
  作者：Javier Martínez-Esparza、Ana-M. Oficialdegui、Silvia Pérez-Silanes、Begoña Heras、Lara Orús、Juan-A. Palop、Berta Lasheras、Joan Roca、Marisa Mourelle、Ana Bosch、Juan-C. Del Castillo、Rosa Tordera、Joaquín Del Río、Antonio Monge

  DOI：10.1021/jm001059j

  日期：2001.2.1

  In a search toward new and efficient antidepressants, 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives were designed, synthesized, and evaluated for 5-HT reuptake inhibition and 5-HT1A receptor antagonism. This dual pharmacological profile should lead, in principle, to a rapid and pronounced enhancement in serotoninergic neurotransmission and consequently to a more efficacious treatment of depression

  为了寻求新的有效的抗抑郁药，设计，合成了1-芳基-3-（4-芳基哌嗪-1-基）丙烷衍生物，并对5-HT再摄取抑制和5-HT1A受体拮抗作用进行了评估。原则上，这种双重药理学特征应导致5-羟色胺能神经传递的快速而明显的增强，从而导致抑郁症的更有效治疗。该设计基于与抑制5-羟色胺再摄取有关的结构部分，例如γ-苯氧基丙胺，与典型的5-HT1A配体芳基哌嗪偶联。在结合研究中，几种化合物对5-HT转运蛋白和5-HT1A受体表现出亲和力。在两个结合研究中，最初在强迫游泳试验中使用Ki <200 nM的那些化合物测定了抗抑郁样活性。通过测量对小鼠直肠温度的内在作用以及对8-OH-DPAT诱导的体温过低的拮抗作用，进行功能表征。进一步研究了最有效的化合物（12f，23gE，28a和28b）在表达5-HT1A受体的细胞系中拮抗8-OH-DPAT诱导的福斯科林刺激的cAMP形成的抑制作用。此外，还在后天研究中
• The Landscape of the Anti-Kinase Activity of the IDH1 Inhibitors
  作者：Katarzyna Malarz、Jacek Mularski、Marcin Pacholczyk、Robert Musiol

  DOI：10.3390/cancers12030536

  日期：——

  Isocitrate dehydrogenases constitute a class of enzymes that are crucial for cellular metabolism. The overexpression or mutation of isocitrate dehydrogenases are often found in leukemias, glioblastomas, lung cancers, and ductal pancreatic cancer among others. Mutation R132H, which changes the functionality of an enzyme to produce mutagenic 2-hydroxyglutarate instead of a normal product, is particularly important in this field. A series of inhibitors were described for these enzymes of which ivosidenib was the first to be approved for treating leukemia and bile duct cancers in 2018. Here, we investigated the polypharmacological landscape of the activity for known sulfamoyl derivatives that are inhibitors, which are selective towards IDH1 R132H. These compounds appeared to be effective inhibitors of several non-receptor kinases at a similar level as imatinib and axitinib. The antiproliferative activity of these compounds against a panel of cancer cells was tested and is explained based on the relative expression levels of the investigated proteins. The multitargeted activity of these compounds makes them valuable agents against a wide range of cancers, regardless of the status of IDH1.

  异柠檬酸脱氢酶是一类对细胞代谢至关重要的酶。异柠檬酸脱氢酶的过表达或突变常见于白血病、胶质母细胞瘤、肺癌和导管性胰腺癌等疾病中。突变R132H可改变酶的功能，产生致突变性的2-羟基戊二酸，而非正常产物，这在该领域尤为重要。已描述了一系列针对这些酶的抑制剂，其中ivosidenib是2018年首个获批用于治疗白血病和胆管癌的药物。我们研究了已知磺胺基衍生物的多药效活性，这些抑制剂对IDH1 R132H具有选择性。这些化合物显示出对几种非受体激酶的有效抑制作用，水平与伊马替尼和阿希替尼相似。对这些化合物在一系列癌细胞中的抗增殖活性进行了测试，并根据所研究蛋白质的相对表达水平进行了解释。这些化合物的多靶活性使它们成为抗多种癌症的有价值药物，不受IDH1状态的影响。
• Hydroquinone derivatives
  申请人：Senju Pharmaceutical Co., Ltd.

  公开号：US06358515B2

  公开（公告）日：2002-03-19

  A hydroquinone compound is represented by the following formula or a pharmacologically acceptable salt thereof with W, R, R1-4, and B1-2 defined herein.

  一种氢醌化合物由以下公式或其药理学上可接受的盐与W、R、R1-4和B1-2在此定义。